Released Aug 14, 2013, after the close
10-Q filed Aug 14, 2013, 45 days after period end · 0001019687-13-003135
Q2 2013 · 10-Q
Revenue$5.53M$5.53M +91,870.1% vs Q2 2012−9.5% vs Q1 2013
Net Income-$99.00K-$99.00K N/M vs Q2 2012N/M vs Q1 2013
EPS Diluted$0.00$0.00 N/M vs Q2 2012N/M vs Q1 2013
Operating Income-$115,000N/M
Operating Cash Flowderived$180,000−47.4%
Free Cash Flowderived$53,000N/M
Margins · derived
Operating margin-2.1%+10687.9 pt vs Q2 2012
Net margin-1.8%+10521.9 pt vs Q2 2012
What the release said
The release
Same quarter
| Metric | Q2 2013 | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|---|
| Revenue | $5.53M | $6.02K | $6.07K | $6.19M |
| Net Income | -$99.00K | -$633.00K | -$984.00K | -$457.00K |
| EPS Diluted | $0.00 | -$0.01 | -$0.02 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR